Scarica l'app Stockscreener
4.21
4.10%
-0.18
Aptevo Therapeutics Inc Borsa (APVO) Ultime notizie
APVO|Aptevo Therapeutics Inc|Price:4.209|Chg%:-0.181 - TradingKey
Aptevo Therapeutics Unveils New Solid Tumor Strategy - TipRanks
Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey
Aptevo files patent for Nectin-4 x PD-L1 cancer platform - Investing.com
Aptevo Filing May Support Radiopharmaceuticals and T-Cell Engagers - Stock Titan
Aptevo Therapeutics Inc (APVO) Cash Flow - TradingKey
Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aptevo Therapeutics Inc (APVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Aptevo Therapeutics Inc. Revenue Breakdown – NASDAQ:APVO - TradingView
Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
APVO|Aptevo Therapeutics Inc|Price:4.390|Chg%:+0.020 - TradingKey
Mary Jo Janatpour Net Worth (2026) - GuruFocus
Niowave, Inc. Net Worth (2026) - GuruFocus
Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aptevo Therapeutics (APVO) Edges Higher: Testing Key Resistance Amid Steady VolumeBPI Reversal - dars.gov.et
Aptevo Therapeutics Secures Grant for APVO451 Development - The Globe and Mail
Grant supports Aptevo’s immunotherapy APVO-451 for solid tumors - BioWorld News
Aptevo (NASDAQ: APVO) gets $1.5M CARE Fund grant to advance APVO451 - Stock Titan
Aptevo receives $1.5M grant for cancer therapy development - Investing.com
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - The Joplin Globe
Aptevo gets $1.5M grant to advance a trispecific cancer drug - Stock Titan
Price to sales forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to sales forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics (APVO) Edges Lower, Testing Key Support LevelsFlat Correction - dars.gov.et
Price to book forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
APVO Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Enterprise value to EBIT forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to earnings forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (NASDAQ:APVO) - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (MUN:AP82) - TradingView
Aptevo Therapeutics (APVO) Gains 2.73% as Shares Test Key Resistance Near $4.95Corrective Wave - dars.gov.et
Aptevo Therapeutics, Inc. Actuals & Estimates (FWB:AP82) - TradingView
AP82 Forecast — Price Target — Prediction for 2027 - TradingView
Form 13G Aptevo Therapeutics Inc. For: 22 June By Investing.com - Investing.com South Africa
Niowave holds 12.18% of Aptevo (NASDAQ: APVO) — 151,723 shares - Stock Titan
NIOWAVE, INC. (NASDAQ: APVO) discloses 98,522 shares and $8 warrants - Stock Titan
Aptevo Therapeutics Inc (APVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com
- The Legal Advocate
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Approach Support at $4.66Volume Climax - dars.gov.et
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate
Aptevo Therapeutics (APVO) Holds Near Support After Modest DeclineHedge Fund Favorites - dars.gov.et
Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate
Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate
Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares - Stock Titan
Aptevo names Mary Janatpour as chief scientific officer - Investing.com UK
Aptevo Therapeutics Names Mary Janatpour Chief Scientific Officer as It Expands Beyond Core Immuno-Oncology Programs - citybiz
Aptevo names Mary Janatpour as chief scientific officer By Investing.com - Investing.com Nigeria
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):